Around a third of all epilepsy patients do not adequately respond to available medication. The GO-Bio initial project EpiTher2 is utilising the discovery of a previously unknown resistance mechanism to develop new therapeutic approaches for this patient group.

The GO-Bio initial joint project NEUROLITH-2 develops an implantable therapy system for the causal treatment of traumatic spinal cord injuries. The aim is to specifically modulate the acute and secondary damage processes following an injury, thus laying the foundations for new treatment options for paraplegia.

The GO-Bio initial project proP develops novel proproteins as dual agonists and antagonists for the tissue-specific regulation of key metabolic processes. The aim is to create a new therapeutic platform for type 2 diabetes and associated metabolic disorders.

The GO-Bio initial project MATRIXCURE-2 develops novel low-molecular-weight active substances against the Sudan virus (SUDV), an orthoebolavirus. The focus is on the targeted inhibition of the viral matrix protein VP40 as a key target for antiviral therapy.

The GO-Bio initial joint project NTSC-2 develops new therapeutic strategies to combat gonococcal infections (gonorrhoea). The focus is on the further development of the antibiotic candidate Darobactin to specifically address resistance in Neisseria gonorrhoeae.

The GO-Bio initial joint project WITS-2 develops a novel sensor technology designed to wirelessly read biochemical signals directly from living cells. The aim is to create a platform technology for highly sensitive, continuous and minimally invasive measurements in research and diagnostics.

The CARE-2 project at Friedrich Schiller University Jena develops an antidepressant with a new mechanism of action based on a newly discovered biological signalling pathway. It is intended to treat depression more quickly and with fewer side effects than existing medicines.

The GO-Bio initial project ReRetina2 develops a method for the rapid production of functional human cone photoreceptor cells from stem cells. The aim is to provide a potential cell replacement therapy for age-related macular degeneration (AMD), a currently incurable cause of blindness.

An overview of the newly selected GO-Bio initial Conceptual Stage Phase 6 projects, presenting early-stage research initiatives supported in this funding period.

An overview of the newly selected GO-Bio Conceptual Stage Phase 5 projects, presenting early-stage research initiatives supported in this funding period.

The ki-alz-2 project is developing an AI-powered tool that combines imaging and cognitive data to detect dementia early and accurately. This innovative approach enables personalized diagnosis and supports timely treatment – crucial for slowing the progression of Alzheimer’s disease.

The microbeam therapy project is advancing a groundbreaking form of radiotherapy that targets tumours with ultra-precise, high-intensity X-ray beams – sparing healthy tissue and requiring only a single treatment session. The
goal: to bring this promising technology from lab to clinic

The VIVA-VEK-2 project is developing an innovative vaccine against RSV using mouse cytomegalovirus (MCMV) vector technology. This platform shows promise for providing durable immunity after a single dose and could play a key role in preparing for future pandemics.

The TumiKo-ZAP 2 project is developing a groundbreaking medical device that activates immune cells directly through the skull bone – before surgery. This minimally invasive interface enables precise delivery of therapies and real-time monitoring, offering a new, integrated approach to treating malignant brain tumours.

The SIC-2 project is developing a next-generation implant to prevent strokes caused by atrial fibrillation. With an adjustable design and integrated sensors to detect and eliminate leaks, it promises safer and more effective closure of the left atrial appendage – marking a major step forward in cardiovascular care.

The RaidoGene-2 project has developed a groundbreaking PET labelling method to precisely track cell and gene therapies in the body. With unmatched sensitivity and specificity, it enables reliable detection of even the smallest therapeutic cell clusters – enhancing both development and clinical use of advanced therapies.

The Plantman project is developing a novel therapy that uses a modified plant protein to break down toxic Huntington’s disease proteins directly. This groundbreaking approach could move the field beyond symptom relief – toward a potential cure.

The MoProX-2 project is pioneering a novel drug discovery approach using molecular glues to target previously inaccessible proteins – opening new therapeutic possibilities, especially for hard-to-treat cancers where conventional drugs fail.

The LyoThroReg project is revolutionizing cell culture with freeze-dried human platelet lysate (HPL). Sourced from expired blood donations, this stable, energy-efficient supplement replaces fetal calf serum – offering ethical and sustainable benefits for research and cell therapy.

The LigaBraid-2 project is developing fully resorbable, tissue-engineered scaffolds to restore torn anterior cruciate ligaments (ACLs). Designed to support natural healing and gradually break down in the body, these braided implants offer a promising alternative to current surgical methods with fewer complications.